Bayer's Pipeline Momentum Faces a Courtroom Deadline

Bayer awaits a U.S. court ruling on its USD 7.25 billion Roundup settlement as new drug approvals and debt cuts reshape the investment case.

Bayer investors are juggling two very different calendars this autumn. One is set by a U.S. judge weighing the company's sprawling Roundup settlement; the other is dictated by oncology launch curves and a Japanese regulatory docket. How those timelines converge — or collide — will shape the stock's next leg.

The legal clock is the more immediate. Following last Monday's hearing on the proposed mass settlement, a ruling is not expected before late September and will more likely land sometime in October, according to media reports. The stakes are considerable: the deal provides for payments of up to USD 7.25 billion, stretched across as many as 21 years in declining, capped annual tranches. A final sign-off would hand the DAX-listed group a degree of financial predictability it has lacked for years.

Fresh Approvals Reshape the Story

While the courtroom drama grinds on, Bayer's pharmaceutical engine has been generating its own headlines. Sevabertinib, marketed as Hyrnuo, won FDA approval last Thursday as an initial treatment option for HER2-mutated non-squamous non-small cell lung cancer (NSCLC). Japan had already cleared the drug for all lines of therapy a few weeks earlier. Separately, roughly two weeks ago, the company filed for Japanese approval of Kerendia (finerenone) in non-diabetic chronic kidney disease, backed by positive Phase 3 data.

Those wins have shifted how the market frames the company. For months, legal legacy issues dominated the narrative; now pipeline substance is clawing back attention. Barclays responded last Friday by lifting its price target to EUR 70 from EUR 60, keeping a buy rating on the shares.

Where the Stock Stands

The equity trades at EUR 49.26, up 33% year to date, though it remains about 9.3% below its 52-week high of EUR 53.86. The central question for holders is whether revenue from new products like Hyrnuo and Kerendia can scale quickly enough to shoulder the looming glyphosate obligations without crimping the wider group's room to maneuver.

The bull case rests on Hyrnuo becoming a dependable oncology revenue driver now that both the U.S. and Japanese markets are open. A first-line designation widens the addressable population considerably compared with follow-on approvals, and a mid-term label expansion for Kerendia in non-diabetic CKD would broaden the pharma division's earnings base further. On the legal side, a final approval would convert the annual cash drain into something calculable and spread over time — the combination Barclays sees as fuel for a run toward EUR 70.

The Bear Case Hinges on Judicial Risk

That optimism carries a caveat: last Monday's hearing does not equal a binding order. Should the court reject the proposed class settlement or demand revisions, the specter of open U.S. litigation returns in full force, leaving the financial burden unpredictable and the hoped-for legal calm deferred. Commercial execution is a second vulnerability — regulatory clearance is no guarantee of market penetration. Hyrnuo must compete in the U.S. and negotiate reimbursement with payers. A sluggish launch, or delays to the Kerendia filing in Japan, would pit fixed legacy liabilities against weaker-than-hoped cash generation, and the recent rally could fizzle.

Balance Sheet Gets a Rewrite

Running parallel to the legal track, management has been reworking the company's financial foundation. Under CFO Judith Hartmann, who took the role on June 1, Bayer trimmed its net debt guidance for the year. It now expects liabilities of EUR 29 billion to EUR 30 billion in 2026, down from a prior forecast of EUR 32 billion to EUR 33 billion. Central to that reduction is a partnership with financial investor Apollo, which is injecting EUR 3.0 billion into a subsidiary housing the long-acting contraceptive business. Bayer retains majority ownership and operational control of the unit.

Operations have held up as well. In the first half of 2026, currency- and portfolio-adjusted group revenue rose 3.3% to EUR 24.277 billion, while adjusted EBITDA before special items climbed 6.6% to EUR 6.597 billion. Full-year guidance was reaffirmed, with Bayer still targeting adjusted EBITDA of EUR 9.6 billion to EUR 10.1 billion. The company also continues to spend on growth: to strengthen its ophthalmology pipeline, it acquired biopharma firm Perfuse Therapeutics.

What to Watch Next

So long as the market trusts that the settlement will be confirmed and Hyrnuo's U.S. rollout stays on schedule, the stock's upward trend should hold. Reaching Barclays' EUR 70 target, however, requires the legal green light to actually arrive and no major new risks to surface. If the USD 7.25 billion settlement collapses at the approval stage, the valuation discount could widen again in short order. The next real test of operating health comes on November 3, 2026, when Bayer publishes its third-quarter statement — a window into how pharma sales are tracking and how management sizes the remaining financial burden.